Therapeutic Advantage of Targeting PRMT5 in Combination with Chemotherapies or EGFR/HER2 Inhibitors in Triple-Negative Breast Cancers by Dakroub R, Huard S, Hajj-Younes Y, Suresh S, Badran B, Fayyad-Kazan H, Dubois T

Get full text

Global microRNA expression profiling identifies MiR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer by Rothé, F, Ignatiadis, M, Chaboteaux, C, Haibe-Kains, B, Kheddoumi, N, Majjaj, S, Badran, B, Fayyad-Kazan, H, Desmedt, C, Harris, A, Piccart, M, Sotiriou, C